Presentation is loading. Please wait.

Presentation is loading. Please wait.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Published byRasmus Håland Modified over 6 years ago

Similar presentations

Presentation on theme: "Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina."— Presentation transcript:

1 Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial 
Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina Gorczyza, MD, Sebastian Zimmer, MD, Petra Staubach, MD, Hans F. Merk, MD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 3, Pages e5 (September 2017) DOI: /j.jaci Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Omalizumab is effective in cold urticaria. CTTs were assessed using TempTest and mean reduction in CTTs from baseline at the primary end point at week 10 (A) and mean absolute values at every investigated time point are shown (B). Omalizumab 150 mg, omalizumab 300 mg, or placebo was injected subcutaneously 3 times every 4 weeks (indicated by an arrow). The star indicates the primary end point readout 2 weeks after the last injection. C, Individual provocation thresholds before and after treatment. Individual CTTs before and after treatment were assessed using TempTest. n.s., Not significant. *P < .05, **P < .01, and ***P < .005. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig E1 Trial profile. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina."

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
What drives prescription patterns in pediatric asthma management?

What drives prescription patterns in pediatric asthma management?
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Dennis K. Ledford, MD, Sally Wenzel, MD 

Dennis K. Ledford, MD, Sally Wenzel, MD 
Shyam Joshi, MD, David A. Khan, MD 

Shyam Joshi, MD, David A. Khan, MD 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Similar presentations

Ads by Google